ANTX Narrows Losses Amid Sharp R&D Spending Cut

Ticker: ANTX · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 1880438

Sentiment: mixed

Topics: Biotechnology, Pharmaceuticals, R&D Spending, Net Loss, Cash Runway, Clinical Trials, Liquidity

TL;DR

**ANTX is cutting R&D to extend its cash runway, but this slowdown could jeopardize its long-term pipeline and competitive standing.**

AI Summary

AN2 Therapeutics, Inc. (ANTX) reported a net loss of $6.46 million for the three months ended June 30, 2025, a significant improvement from the $14.44 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $17.11 million, down from $31.05 million in the prior year. This reduction in loss was primarily driven by a substantial decrease in research and development (R&D) expenses, which fell to $3.20 million for the three months ended June 30, 2025, from $12.15 million in 2024, and to $10.89 million for the six months ended June 30, 2025, from $26.80 million in 2024. General and administrative expenses slightly increased to $4.02 million for the quarter, up from $3.73 million. The company's cash, cash equivalents, and investments stood at $71.2 million as of June 30, 2025, down from $86.26 million at December 31, 2024. Management believes current capital is sufficient to fund operations for at least 12 months from the issuance date of these financial statements. The accumulated deficit grew to $222.89 million as of June 30, 2025, from $205.78 million at December 31, 2024.

Why It Matters

For investors, AN2 Therapeutics' significant reduction in net loss and R&D spending indicates a strategic shift, potentially towards conserving capital or focusing on fewer, more promising pipeline assets. This could be a double-edged sword: while it extends the company's cash runway, it also signals a slowdown in the pace of drug development, which is critical for a biopharmaceutical company. Competitively, a reduced R&D spend might put ANTX at a disadvantage against rivals with more aggressive development timelines, impacting its ability to bring novel boron-based compounds for diseases like Chagas or NTM lung disease to market. Employees might face uncertainty regarding future project scope, and customers could see delays in potential new treatments.

Risk Assessment

Risk Level: medium — The company's risk level is medium due to its continued significant net losses, with an accumulated deficit of $222.89 million as of June 30, 2025. While cash, cash equivalents, and investments of $71.2 million are projected to last at least 12 months, the substantial reduction in R&D spending from $26.80 million to $10.89 million year-over-year for the six months ended June 30, 2025, suggests a constrained financial environment that could impact future product development.

Analyst Insight

Investors should closely monitor ANTX's future R&D expenditures and clinical trial progress. While the reduced burn rate is positive for short-term liquidity, a sustained low R&D investment could signal a lack of confidence in its pipeline or an inability to secure further financing, making it a speculative long-term hold.

Financial Highlights

debt To Equity
N/A
revenue
N/A
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$6.46M
eps
N/A
gross Margin
N/A
cash Position
$71.2M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What were AN2 Therapeutics' net losses for the three and six months ended June 30, 2025?

AN2 Therapeutics reported a net loss of $6.46 million for the three months ended June 30, 2025, and a net loss of $17.11 million for the six months ended June 30, 2025. This represents a significant improvement compared to net losses of $14.44 million and $31.05 million for the respective periods in 2024.

How did AN2 Therapeutics' research and development expenses change in the first half of 2025?

Research and development expenses for AN2 Therapeutics decreased substantially. For the three months ended June 30, 2025, R&D was $3.20 million, down from $12.15 million in the same period of 2024. For the six months ended June 30, 2025, R&D expenses were $10.89 million, a significant reduction from $26.80 million in the first half of 2024.

What is AN2 Therapeutics' current cash position and how long is it expected to last?

As of June 30, 2025, AN2 Therapeutics had cash, cash equivalents, and investments totaling $71.2 million. Management believes this capital will be sufficient to fund its current operating plan through at least 12 months from the issuance date of these condensed financial statements.

What is AN2 Therapeutics' accumulated deficit as of June 30, 2025?

AN2 Therapeutics' accumulated deficit increased to $222.89 million as of June 30, 2025. This is up from $205.78 million as of December 31, 2024, reflecting the ongoing net losses incurred by the company.

What are the primary business activities of AN2 Therapeutics, Inc.?

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics from its boron chemistry platform. Its pipeline includes boron-based compounds for Chagas disease, melioidosis, and non-tuberculous mycobacterial (NTM) lung disease caused by M. abscessus, along with programs in oncology and infectious diseases.

Has AN2 Therapeutics raised capital recently through equity offerings?

Yes, AN2 Therapeutics entered into an at-the-market (ATM) offering on April 6, 2023, to sell up to $100.0 million in common stock, generating net proceeds of $19.1 million in 2023. Additionally, on August 15, 2023, the company completed an underwritten offering of 7,777,778 shares of common stock at $9.00 per share, resulting in net proceeds of $65.5 million.

What are the main risks to AN2 Therapeutics' liquidity?

The main risks to AN2 Therapeutics' liquidity stem from its history of significant losses and negative cash flows from operations, with an accumulated deficit of $222.89 million. Future capital requirements are substantial for R&D, and there's no assurance that additional financing will be available on acceptable terms, which could materially affect its business objectives.

How many shares of common stock did AN2 Therapeutics have outstanding as of August 4, 2025?

As of August 4, 2025, AN2 Therapeutics, Inc. had 27,326,165 shares of common stock, with a par value of $0.00001 per share, outstanding.

What was the change in cash flows from operating activities for AN2 Therapeutics in the first six months of 2025 compared to 2024?

For the six months ended June 30, 2025, AN2 Therapeutics used $18.22 million in cash from operating activities. This is a notable improvement from the $31.98 million used in operating activities during the same period in 2024, indicating a reduced cash burn from core operations.

What is the significance of AN2 Therapeutics being an 'emerging growth company'?

As an emerging growth company under the JOBS Act, AN2 Therapeutics may elect to use an extended transition period for complying with new or revised financial accounting standards. This designation provides certain regulatory relief and reduced disclosure requirements, potentially lowering compliance costs and administrative burdens.

Risk Factors

Industry Context

AN2 Therapeutics operates in the highly competitive biopharmaceutical sector, specifically focusing on oncology. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies like AN2 Therapeutics are driven by innovation in novel therapeutic approaches, facing competition from both large established pharmaceutical firms and other emerging biotech companies.

Regulatory Implications

The company's progress is subject to the rigorous approval processes of regulatory bodies such as the FDA. Delays or failures in clinical trials or the inability to meet stringent safety and efficacy standards can significantly impede product development and market entry, posing a substantial risk to the company's future.

What Investors Should Do

  1. Monitor R&D Spending and Pipeline Progress
  2. Assess Future Funding Needs
  3. Evaluate Competitive Landscape

Key Dates

Glossary

Accumulated Deficit
The total net losses of a company since its inception, minus any net gains. It represents the cumulative losses that have not been offset by profits. (Indicates the company's historical unprofitability and the extent of capital required to fund operations.)
Research and Development (R&D) Expenses
Costs incurred by a company in the process of developing new products or services, or improving existing ones. For biotech companies, this includes clinical trials, lab work, and drug discovery. (A major expense category for AN2 Therapeutics, its reduction signifies a strategic shift or cost-saving measure impacting future growth potential.)
Cash, Cash Equivalents, and Investments
Represents the most liquid assets a company holds, including cash on hand, bank deposits, short-term marketable securities, and other highly liquid instruments. (Crucial for assessing the company's short-term financial health and its ability to fund ongoing operations and R&D.)
Net Loss
The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (Shows the company's profitability (or lack thereof) for the reporting period. A reduction in net loss is a positive sign, but the company remains unprofitable.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, AN2 Therapeutics has significantly reduced its net loss, with Q2 2025 net loss at $6.46 million versus $14.44 million in Q2 2024, and YTD net loss at $17.11 million versus $31.05 million. This improvement is primarily driven by a substantial reduction in R&D expenses, which fell from $12.15 million to $3.20 million for the quarter and from $26.80 million to $10.89 million year-to-date. General and administrative expenses saw a slight increase. The company's cash position has decreased, and its accumulated deficit has grown, reflecting ongoing investment in its development pipeline.

Filing Stats: 4,440 words · 18 min read · ~15 pages · Grade level 16.8 · Accepted 2025-08-12 16:06:34

Key Financial Figures

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Balance Sheets 3 Condensed Statements of Operations and Comprehensive Loss 4 Condensed Statements of Stockholders' Equity 5 Condensed Statements of Cash Flows 7 Notes to Unaudited Condensed Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 38 Item 4.

Controls and Procedures

Controls and Procedures 39 PART II. OTHER INFORMATION 41 Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 95 Item 3. Defaults Upon Senior Securities 95 Item 4. Mine Safety Disclosures 95 Item 5. Other Information 95 Item 6. Exhibits 97

Signatures

Signatures 99 i SPECIAL NOTE REGA RDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q ("Form 10-Q") contains forward-looking statements. All statements other than statements of historical facts contained in this Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical and nonclinical studies and clinical trials, results of preclinical and nonclinical studies, clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential," or "continue," or the negative of these terms or other similar expressions. Forward-looking statements contained in this Form 10-Q include, but are not limited to, statements about: the initiation, timing, progress, and results of our preclinical and nonclinical studies and clinical trials, and our research and development programs, including the manufacture of clinical trial material and drug product for launch; the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements; the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing; our use of the net proceeds from financing activities; the outcome of potential interactions w

—FIN ANCIAL INFORMATION

PART I—FIN ANCIAL INFORMATION Ite m 1. Financial Statements. AN2 THERAPEUTICS, INC. CONDENSED BALANCE SHEETS (in thousands, except share and per share amounts) (unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 18,220 $ 21,351 Short-term investments 44,696 62,267 Prepaid expenses and other current assets 4,608 2,644 Total current assets 67,524 86,262 Long-term investments 8,301 5,021 Other assets, long-term — 804 Total assets $ 75,825 $ 92,087 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,113 $ 3,317 Accrued compensation 1,199 1,676 Accrued liabilities 2,954 4,454 Other current liabilities 717 791 Total liabilities 6,983 10,238 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock, $ 0.00001 par value; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.00001 par value; 500,000,000 shares authorized at June 30, 2025 and December 31, 2024; 27,376,461 and 29,919,634 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively — — Additional paid-in capital 291,704 287,594 Accumulated other comprehensive gain 25 31 Accumulated deficit ( 222,887 ) ( 205,776 ) Total stockholders' equity 68,842 81,849 Total liabilities and stockholders' equity $ 75,825 $ 92,087 The accompanying notes are an integral part of these unaudited interim condensed financial statements. 3 AN2 THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share amounts) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 3,200 $ 12,149 $ 10

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing